A Potential Application of Canaloplasty in Glaucoma Gene Therapy.

PubMed ID: 23888250

Author(s): Tian B, Kaufman PL. A potential application of canaloplasty in glaucoma gene therapy. Transl Vis Sci Technol. 2013 Jan 31;2(1). pii: 2. PMID 23888250

Journal: Translational Vision Science & Technology, Volume 2, Issue 1, Jan 2013

Canaloplasty, a recently developed non-penetrating glaucoma surgical approach, may restore physiological outflow routes in primary open-angle glaucoma with less risk of severe postoperative complications than trabeculectomy. Since the inner wall of Schlemm’s canal (SC) is directly in contact with the trabecular meshwork (TM) for 360 degrees and the catheter device used in canaloplasty allows viscoelastic to be injected into the entire length of SC, canaloplasty might also be used to perform SC/TM-targeted delivery of transgene vectors for glaucoma gene therapy. This hypothesized new method for transgene delivery may give the transgene access to the entire inner wall of SC and the whole juxtacanalicular region of the TM and allow the transgene to be expressed in both the TM and SC without affecting the cornea, iris and ciliary body. Further, this strategy might have a greater trabecular outflow resistance-decreasing effect than either the genetic or surgical approach alone.